- Home
- NUKK vs SGMT Comparison
NUKK vs SGMT Comparison
Compare NUKK & SGMT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NUKK
- SGMT
- Stock Information
- Founded
- NUKK 2013
- SGMT 2006
- Country
- NUKK United States
- SGMT United States
- Employees
- NUKK N/A
- SGMT N/A
- Industry
- NUKK Blank Checks
- SGMT
- Sector
- NUKK Finance
- SGMT
- Exchange
- NUKK Nasdaq
- SGMT Nasdaq
- Market Cap
- NUKK 77.4M
- SGMT 71.2M
- IPO Year
- NUKK N/A
- SGMT 2023
- Fundamental
- Price
- NUKK $13.63
- SGMT $3.62
- Analyst Decision
- NUKK
- SGMT Strong Buy
- Analyst Count
- NUKK 0
- SGMT 6
- Target Price
- NUKK N/A
- SGMT $25.67
- AVG Volume (30 Days)
- NUKK 235.9K
- SGMT 392.3K
- Earning Date
- NUKK 06-10-2025
- SGMT 05-08-2025
- Dividend Yield
- NUKK N/A
- SGMT N/A
- EPS Growth
- NUKK N/A
- SGMT N/A
- EPS
- NUKK N/A
- SGMT N/A
- Revenue
- NUKK N/A
- SGMT N/A
- Revenue This Year
- NUKK N/A
- SGMT N/A
- Revenue Next Year
- NUKK N/A
- SGMT N/A
- P/E Ratio
- NUKK N/A
- SGMT N/A
- Revenue Growth
- NUKK N/A
- SGMT N/A
- 52 Week Low
- NUKK $1.30
- SGMT $1.73
- 52 Week High
- NUKK $78.32
- SGMT $7.38
- Technical
- Relative Strength Index (RSI)
- NUKK 41.12
- SGMT 57.81
- Support Level
- NUKK $13.05
- SGMT $3.18
- Resistance Level
- NUKK $26.21
- SGMT $3.85
- Average True Range (ATR)
- NUKK 2.37
- SGMT 0.27
- MACD
- NUKK -0.56
- SGMT 0.01
- Stochastic Oscillator
- NUKK 3.91
- SGMT 61.04
About NUKK Nukkleus Inc.
Nukkleus Inc is a financial technology company that is focused on providing software and technology solutions. The company's operating segment includes General support services and Financial services. General support services include providing software, technology, customer sales and marketing, and risk management technology hardware and software solutions package under a GSA to a related party. Financial services include providing payment services from one fiat currency to another or to digital assets. It generates maximum revenue from the General support services segment. Geographically operates in USA, UK and Malta, with majority of revenue from United Kingdom (UK).
About SGMT Sagimet Biosciences Inc. Series A
Sagimet Biosciences Inc is a clinical-stage biopharmaceutical company dedicated to developing a portfolio of in-house discovered, selective fatty acid synthase (FASN) inhibitors aimed at treating diseases that arise from dysfunctional lipid metabolism pathways. The company's drug candidate, denifanstat, is an oral, once-daily pill that serves as a selective FASN inhibitor under development for treating nonalcoholic steatohepatitis (NASH). The company functions as a single business segment, focusing on the development and commercialization of therapeutics for MASH and other diseases where FASN plays a pathogenic role.